== Adverse effects ==

 
The dose-limiting side effects include [[paresthesia|tingling or numbness]], difficulty sleeping, fatigue, and loss of muscle strength.<ref name=Tarr2015rev/>

 
The licensing of Firdapse in 2010 in Europe led to a sharp increase in price for the drug. In some cases, this has led to hospitals using an unlicensed form rather than the licensed agent, as the price difference proved prohibitive. BioMarin has been criticized for licensing the drug on the basis of previously conducted research, and yet charging exorbitantly for it.<ref>{{cite news|last1=Goldberg|first1=Adrian|title=Drug firms accused of exploiting loophole for profit|url=http://www.bbc.com/news/health-11798183|work=BBC News|date=21 November 2010}}</ref>  A group of UK neurologists and pediatricians petitioned to prime minister [[David Cameron]] in an open letter to review the situation.<ref name=Nichol>{{cite journal | vauthors = Nicholl DJ, Hilton-Jones D, Palace J, Richmond S, Finlayson S, Winer J, Weir A, Maddison P, Fletcher N, Sussman J, Silver N, Nixon J, Kullmann D, Embleton N, Beeson D, Farrugia ME, Hill M, McDermott C, Llewelyn G, Leonard J, Morris M | title = Open letter to prime minister David Cameron and health secretary Andrew Lansley | journal = BMJ | volume = 341 | issue =  | pages = c6466 | year = 2010 | pmid = 21081599 | doi = 10.1136/bmj.c6466 | url = http://www.bmj.com/content/341/bmj.c6466.full }}</ref> The company responded that it submitted the licensing request at the suggestion of the French government, and points out that the increased cost of a licensed drug also means that it is monitored by regulatory authorities (e.g. for uncommon side effects), a process that was previously not present in Europe.<ref>{{cite journal | vauthors = Hawkes N, Cohen D | title = What makes an orphan drug? | journal = BMJ | volume = 341 | issue =  | pages = c6459 | year = 2010 | pmid = 21081607 | doi = 10.1136/bmj.c6459 }}</ref>  A 2011 Cochrane review compared the cost of the 3,4-DAP and 3,4-DAPP in the UK and found an average price for 3,4-DAP base of £1/tablet and an average price for 3,4-DAP phosphate of £20/tablet; and the authors estimated a yearly cost per person of £730 for the base versus £29,448 for the phosphate formulation.<ref name=Cochrane2011/><ref name=NHS2015>{{cite web|title=Evidence Review: Amifampridine phosphate for the treatment of Lambert–Easton Myasthenic Syndrome|url=https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave2/user_uploads/d04-x01-amifampridine-ev-review.pdf|publisher=NHS England|date=December 2015}}</ref>
